New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 30, 2014
13:15 EDTEXASExact Sciences could rise 50%, Barron's says
Exact Sciences shares could rise 50% fit the company's colon cancer test ramps up quickly, Barron's contends in a feature article. Short sellers are betting heavily against the company, the paper adds. Reference Link
News For EXAS From The Last 14 Days
Check below for free stories on EXAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
09:32 EDTEXASExact Sciences management to meet with Roth Capital
Meeting to be held in Boston on September 3 hosted by Roth Capital.
08:00 EDTEXASExact Sciences price target raised to $28 from $22 at JMP Securities
JMP Securities increased its price target on Exact Sciences as the firm, after conducting channel checks, estimates that ColoGuard will sell for $375. The firm continues to recommend buying shares of the stock.
August 26, 2014
07:46 EDTEXASExact Sciences price target raised to $23 from $21 at Canaccord
Canaccord raised its price target on Exact Sciences to $23 from $21 following yesterday's announcement the Mayo Clinic will adopt Cologuard. The firm believes there is the potential for additional healthcare systems to come on board as the publicity raises awareness among primary care doctors. Canaccord keeps its Buy rating on shares of Exact Sciences.
August 25, 2014
11:26 EDTEXASOptions with increasing implied volatility: EXAS FTR PSEC
Subscribe for More Information
August 22, 2014
13:31 EDTEXASExact Sciences test not reimbursed by Aetna, says Maxim
Subscribe for More Information
10:07 EDTEXASOptions with increasing implied volatility: ORPH EXAS AZN
Subscribe for More Information
August 20, 2014
11:47 EDTEXASOptions with increasing implied volatilit
Subscribe for More Information
August 18, 2014
08:05 EDTEXASExact Sciences risk/reward positive, says Canaccord
Canaccord said the scenario analysis of upcoming catalysts suggests positive risk/reward for the shares of Exact Sciences. The firm cited its potential for reimbursement approvals form both the CMS and commercial payers. Shares of Exact Sciences remain Buy rated with a $21 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use